TY - JOUR
T1 - SGLT2 inhibitor and GLP-1 receptor agonist combination therapy substantially improved the renal function in a patient with type 2 diabetes
T2 - Implications for additive renoprotective effects of the two drug classes
AU - Nonomura, Kenta
AU - Iizuka, Katsumi
AU - Kuwabara-Ohmura, Yayoi
AU - Yabe, Daisuke
N1 - Publisher Copyright:
© 2020 The Japanese Society of Internal Medicine.
PY - 2020/6/15
Y1 - 2020/6/15
N2 - A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.
AB - A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.
KW - Diabetic kidney disease
KW - Estimated glomerular filtration rate
KW - GLP-1 receptor agonist
KW - SGLT2 inhibitor
KW - Type 2 diabetes mellitus
UR - https://www.scopus.com/pages/publications/85086522873
UR - https://www.scopus.com/inward/citedby.url?scp=85086522873&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.4323-19
DO - 10.2169/internalmedicine.4323-19
M3 - Article
C2 - 32188813
AN - SCOPUS:85086522873
SN - 0918-2918
VL - 59
SP - 1535
EP - 1539
JO - Internal Medicine
JF - Internal Medicine
IS - 12
ER -
